---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-022922"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2022-09-22T23:59:59+00:00"
generated_at: "2026-06-23T07:58:05.387907+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Puma Biotechnology licenses alisertib from Takeda; $7M upfront, up to $287.3M in milestones

## Summary
- Entered exclusive global license for alisertib from Takeda; upfront payment of $7 million.
- Potential regulatory and commercial milestones up to $287.3 million, plus tiered royalties.
- Puma responsible for development, manufacturing, and commercialization globally.
- Must use commercially reasonable efforts in US, UK, France, Germany, Italy, Spain, and Japan.
- Puma can terminate on 120 days' notice; Takeda may terminate if Puma halts activities for >12 months.

## SEC filing metadata
- accession: 0001437749-22-022922
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2022-09-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774922022922/0001437749-22-022922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774922022922/pbyi20220922_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-022922
- JSON: https://secwatch.observer/filing/0001437749-22-022922.json
- Plain text: https://secwatch.observer/filing/0001437749-22-022922.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.